Isomorphic Labs Stock Price, Valuation & IPO
Last updated on 8 October 2026Isomorphic Labs is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Source: AXEVIL investment team
Track Isomorphic Labs Stock Price
We monitor the Isomorphic Labs stock price based on the latest private market data and funding rounds. Since there is no Isomorphic Labs stock symbol on public exchanges yet, we provide a consensus price to help you track your investment.
Isomorphic Labs
Isomorphic Labs is a British company designing drugs with AI, spun out of DeepMind in 2021, headquartered in London. It builds on the legacy of AlphaFold: the IsoDDE engine is 2.3 times more accurate than AlphaFold 3 in predicting antibody-target binding, and the design agent completes searches in 2–4 days that take chemists months. Partnerships have been established with Eli Lilly (an upfront payment of $45 million, with milestone payments up to $1.7 billion), Novartis (three targets with an upfront payment of $37.5 million and potential up to $1.2 billion; three more programs were added in 2025) and Johnson & Johnson — the latest agreement from January 2026 brings the company into biologics. A Series B round in May 2026 led by Thrive Capital brought in $2.1 billion, with a total of $2.7 billion raised.
Key highlights
Where Isomorphic Labs stands today across technology, financials and market traction.
Eli Lilly and small molecules.
The January 2024 agreement covers several undisclosed targets. Lilly paid an upfront payment of $45 million, and with milestone payments, the sum reaches up to $1.7 billion.
Novartis doubled the program.
Initially, the companies selected three challenging targets with an upfront payment of $37.5 million and a potential of up to $1.2 billion. In February 2025, Novartis added three more programs, without waiting for the results of the first ones.
Johnson & Johnson and new types of drugs.
The January 20, 2026 agreement covers small molecules, antibodies, peptides, and molecular glues. This allowed Isomorphic to enter biologics, which account for a large share of pharma sales.
News
Frequently Asked Questions
Not on a public exchange — Isomorphic Labs is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
A private company has no single official share price. AXEVIL does not publish a consensus share-price estimate for this company at the moment.
AXEVIL does not have a verified valuation for Isomorphic Labs at the moment; it appears here once a priced round is on record.
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
No. Isomorphic Labs is a private company and its shares are not listed on any public exchange.
No. Isomorphic Labs has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Get Updates
Stay informed about Isomorphic Labs stock news and new investment rounds.
Risk disclosure and data sources
Secondary-market prices and investment round data on this page, current and historical, are based on publicly available information and on data from market participants, and are provided for informational purposes only. Axevil Capital strives for accuracy; all prices and valuations are approximate and may fluctuate significantly due to low liquidity and limited access to information. The secondary market for private company shares is illiquid and does not guarantee the ability to buy or sell shares at the displayed price.
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.
Axevil Capital, LLC is a Delaware limited liability company (registration No. 6832739) operating as an investment adviser relying on an exemption from registration, filed with the SEC as an Exempt Reporting Adviser (SEC file No. 802-126907; CRD No. 323970). ERA status means the Company files reports with the SEC but is not a registered investment adviser. The Company is not a broker-dealer and is not a member of FINRA or SIPC.